

Hackensack
385 Prospect Avenue
Suite 101
Hackensack, NJ, 07601

Princeton / Somerset
49 Veronica Avenue
Suite 202
Somerset, NJ 08873

Long Branch
422 Morris Avenue
Suite 7
Long branch, NJ 07740

Marlton
127 Church Road
Suite 600
Marlton, NJ 08053



KISUNLA™ (donanemab-azbt)

ORDER FORM

Date: _____

PATIENT INFORMATION

Name:	DOB:	SEX: M <input type="checkbox"/> F <input type="checkbox"/>
Phone Number:	Preferred Location:	

POVIDER INFORMATION

Ordering Provider:	Practice Name:	
Address:	Office Contact:	NPI:
Phone:	Fax:	Contact email (required):

REFERRAL STATUS(Check one)

☐ New Referral ☐ Referral Renewal ☐ Updated Order ☐ Transfer of care – Date of last infusion/Next due date

Kisunla:

Kisunla is indicated for the treatment of Alzheimer's disease (AD). Treatment with Kisunla should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials.

Diagnosis ICD-10

Check one:

- ☐ G31.84 Mild Cognitive Impairment, so stated
☐ G30.0 Alzheimer's Disease with early onset
☐ G30.1 Alzheimer's Disease with late onset
☐ G30.8 Other Alzheimer's Disease
☐ G30.9 Alzheimer's Disease, unspecified

Premeds

Select all that apply:

- ☐ Acetaminophen _____mg PO
☐ Cetirizine 10mg PO
☐ Diphenhydramine (check all that apply)
_____25mg _____50mg _____PO _____IV
☐ Methylprednisolone _____mg IV
☐ Dexamethasone _____mg IV
☐ Other:

REQUIRED CLINICAL DOCUMENTATION CHECKLIST

- ____Demographics page with insurance info
____Progress note with cognitive testing within the last 6 months
____Amyloid PET scan or CSF results with amyloid confirmation
____MRI of the brain within the last year
____If Medicare patient, Alzheimer's Registry number
(i.e. ALZH-00000)
____Other

Therapy Administration and Dosing (supplied as 350mg/20mL vial)

All doses will be administered via appropriate final concentration of 4mg/mL to 10mg/mL

Dose #1 – 350mg IV – Administer in 0.9%NS IVPB over at least 30 minutes

Dose #2 – 750mg IV – Administer in 0.9%NS IVPB over at least 30 minutes

Dose #3 – 1050mg IV – Administer in 0.9%NS IVPB over at least 30 minutes

Doses #4-18 – 11400mg IV – Administer in 0.9%ND IVPB over at least 30 minutes

Please indicate here any preferred variation from standard orders including longer infusion times, less doses, etc.

• All patients will be kept for 30 minutes of monitoring following completion of infusion per the guidelines in the PI.

• Please note MRIs to assess for ARIA are required prior to doses 2, 3, 4 and 7 and must be sent to Thrivewell in order for patient to be cleared to proceed with treatment. Failure to provide the required MRI report at least 24hrs prior to the patient's scheduled appointment may result in delay in care for the patient.

Additional Orders: By signing this order, you agree to the following orders unless otherwise noted.

- Hold infusion and notify provider if patient reports: Headache, dizziness, nausea, vision changes, new or worsening confusion, balance concerns, or change in mentation.
- Infusion/allergic reactions may be managed by clinical staff per facility protocol. Provider office will be notified in real time of any infusion reactions.

NOTES/ADDITIONAL COMMENTS:

ORDERING PROVIDER

Signature X _____ Date _____